Exelixis Competitive Intelligence & Landscape

Exelixis (exelixis.com) is a multi-platform oncology company dedicated to the discovery, development, and commercialization of new medicines for cancer [https://exelixis.com/development/]. Founded and incorporated in 1994, the company has evolved over three decades to challenge the status quo in cancer treatment by focusing on both small molecules and biotherapeutics [https://www.exelixis.com/our-story/]. Its mission is to advance science for hope, aiming to create treatment regimens that bring closer a potential cure and give patients hope for the future [https://exelixis.com/].

Exelixis operates with a comprehensive approach, leveraging deep expertise in chemistry and biology, alongside strategic partnerships, to develop diverse biotherapeutics such as bispecific antibodies and antibody-drug conjugates. Their in-house discovery teams are also advancing multiple small molecule programs, including next-generation approaches to established targets and first-in-class opportunities across various modalities and mechanisms of action [https://exelixis.com/]. The company's pipeline and clinical trials are powered by this innovation, with a focus on accelerating new medicines for difficult-to-treat cancers [https://exelixis.com/development/].

The target market for Exelixis is patients with cancer, with a particular emphasis on developing treatments for conditions like metastatic colorectal cancer, as indicated by a U.S. FDA PDUFA date set for December 2026 for an investigational therapy [https://exelixis.com/]. The company’s products include CABOMETYX® (cabozantinib) and COMETRIQ® (cabozantinib) [https://www.exelixis.com/contact-us/].

Exelixis places patients at the center of everything they do, striving to enhance the lives of cancer patients and their caregivers [https://exelixis.com/leadership/].

Exelixis is headquartered at 1851 Harbor Bay Parkway, Alameda, CA 94502 [https://www.exelixis.com/contact-us/]. The company is listed on the NASDAQ Global Select Market under the ticker symbol EXEL [https://ir.exelixis.com/resources/investor-faqs]. With a commitment to an exceptional employee experience and a purpose-driven work environment, Exelixis aims to be a life sciences employer of choice, nurturing a culture of authenticity and growth [https://www.exelixis.com/careers/].

Exelixis's core value proposition is to shape the future of oncology by innovating at the forefront of cancer care. They emphasize a collaborative team approach to fulfilling their promise of oncology innovation excellence, always putting patient and employee needs first. This dedication fuels their global ambition to develop new treatments that enhance the lives of cancer patients [https://exelixis.com/leadership/].

Exelixis (exelixis.com) is an oncology-focused biotechnology company dedicated to developing and commercializing new medicines for difficult-to-treat cancers. Their core product offerings are innovative cancer treatments, stemming from a diverse portfolio of clinically differentiated compounds developed through internal research and strategic external partnerships [https://www.exelixis.com/clinical-trials-pipeline/]. The company emphasizes a science-first, data-driven approach to drug development, aiming to provide meaningful treatments and more hope for patients [https://www.exelixis.com/medicines/].

For employees, Exelixis provides a comprehensive benefits package that includes various health and wellness resources. U.S. employees working at least 30 hours a week are offered two medical plan options, with California employees having an additional Kaiser HMO plan option [https://mybenefits.exelixis.com/health-care-landing-page/medical-plan-options/]. These plans include benefits such as preventive health services at no cost and physician office visits for a co-pay, as detailed in documents like the 2026 Blue Shield EPO [https://mybenefits.exelixis.com/wp-content/uploads/2026/03/2026-Blue-Shield-EPO-EOC-Exelixis-021326.pdf] and the PPO Savings Plan summary [https://mybenefits.exelixis.com/wp-content/uploads/2026/01/2026-Blue-Shield-HDHP-Benefit-Summary-Exelixis-011526.pdf].

Beyond medical coverage, Exelixis's employee benefits extend to financial tools and retirement options, including a 401(k) Retirement Savings Plan, 529 College Savings Plan, and Health Savings Accounts (HSAs) [https://mybenefits.exelixis.com/emotional-and-physical/][https://mybenefits.exelixis.com/]. While these are not pricing plans for their oncology products, they represent the company's internal investment in its workforce. The company does not offer free or paid tiers for its investigational cancer therapies; instead, access is primarily through clinical trials, or in specific appropriate circumstances, via "early access" requests for medicines not yet regulatory approved [https://www.exelixis.com/access-to-investigational-therapies/].

Given that Exelixis operates in the pharmaceutical industry, its "pricing plans" for its primary products, which are oncology drugs, are not structured in a consumer-facing tier system like software or service subscriptions. Instead, drug pricing typically involves complex negotiations with healthcare providers, insurers, and government bodies after regulatory approval. Information regarding specific drug pricing is not publicly disclosed on their website, as is typical for pharmaceutical companies. The focus on their website is on innovation, development, and patient access to investigational therapies [https://www.exelixis.com/development/][https://www.exelixis.com/access-to-investigational-therapies/].

Exelixis (exelixis.com) is actively hiring across various departments, demonstrating a strategic focus on expanding its oncology efforts. The company provides a dedicated careers website where interested candidates can explore openings and notes that it also lists positions on LinkedIn, Glassdoor, and Indeed [https://www.exelixis.com/careers/]. This broad outreach suggests a consistent need for talent to fuel its "discovery, development and commercialization efforts" [https://www.exelixis.com/inside-exelixis/].

A significant portion of Exelixis's job openings are concentrated in Research & Development (R&D), with 32 current positions available [https://www.exelixis.com/careers/job-openings/?departments=&employment_type=&keyword=&location=&view_all=true]. Within R&D, roles such as "Associate Regulatory Operations Director," "Sr Director, Biostatistics," "Executive Director, Scientific Publications (Oncology)," and "Clinical Trials Manager (Oncology)" are listed, indicating a strong emphasis on advancing its pipeline and clinical programs [https://www.exelixis.com/careers/product-development/job-openings/]. This hiring trend in R&D signals Exelixis's commitment to innovating at the "forefront of cancer care" and building "next-generation oncology franchises" [https://www.exelixis.com/inside-exelixis/].

Beyond R&D, Exelixis is also hiring in other key areas, including Pharmaceutical Operations and Supply Chain (4 jobs), Commercial (9 jobs), and General and Administrative (14 jobs) [https://www.exelixis.com/careers/job-openings/?departments=&employment_type=&keyword=&location=&view_all=true]. Featured roles in Commercial include "Associate RCC Marketing Promotions Director" and "Senior Oncology Account Manager" [https://www.exelixis.com/careers/commercial/]. In Pharmaceutical Operations and Supply Chain, positions like "Packaging Engineer I" are highlighted, reflecting the company's need for skilled scientists to manage its global manufacturing network [https://www.exelixis.com/careers/pharmaceutical-operations-and-supply-chain/]. These diverse openings across multiple functions underscore a holistic growth strategy aimed at supporting its entire operational lifecycle from discovery to commercialization.

While specific details on recent layoffs are not provided on the Exelixis website, the current number of job openings across various departments and the explicit statements about expanding "purposeful career growth opportunities" and hiring "across a full spectrum of roles" [https://www.exelixis.com/inside-exelixis/] suggest a period of growth and expansion rather than reduction. The company emphasizes a vibrant culture and the importance of its employees in advancing its mission, further indicating a commitment to talent acquisition and development [https://www.exelixis.com/inside-exelixis/]. This pattern of active hiring across critical functions aligns with Exelixis's overarching mission as a "multi-platform cancer company dedicated to creating treatment regimens that challenge the status quo" [https://www.exelixis.com/inside-exelixis/].

Exelixis demonstrates robust financial performance, with total revenues for fiscal year 2025 reaching $2.320 billion, an increase from $2.17 billion in fiscal year 2024 [https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-fourth-quarter-and-fiscal-year-2025-financial]. The cabozantinib franchise played a significant role in these results, contributing $2.123 billion in U.S. net product revenues for fiscal year 2025 [https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-fourth-quarter-and-fiscal-year-2025-financial], up from $1.81 billion in fiscal year 2024 [https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-fourth-quarter-and-fiscal-year-2024-financial]. For the first quarter of 2026, Exelixis reported total revenues of $610.8 million, with the cabozantinib franchise generating $555.0 million in U.S. net product revenues [https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-first-quarter-2026-financial-results-and].

The company maintains a healthy financial outlook, as evidenced by its GAAP diluted EPS of $2.78 for fiscal year 2025 [https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-fourth-quarter-and-fiscal-year-2025-financial], a notable increase from $1.76 in fiscal year 2024 [https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-fourth-quarter-and-fiscal-year-2024-financial].

Exelixis also announced an additional stock repurchase program, authorizing up to $750 million by the end of 2027, highlighting confidence in its financial strength and future prospects [https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-first-quarter-2026-financial-results-and]. Stockholders' equity at June 30, 2025, included common stock valued at $270 million and additional paid-in capital of $2,251,456 [https://ir.exelixis.com/static-files/c4fb14cf-8e73-4e3e-bc9f-87d946e0aec9].

Exelixis actively engages in collaborations to advance its R&D pipeline. An example includes an agreement with Bristol-Myers Squibb, involving a $5.0 million upfront license fee and $3.0 million per year in research funding for a minimum of three years for the development of XL11 [https://ir.exelixis.com/static-files/bfef2a07-0a4d-4376-b3aa-301dae0ef1ef]. The company also provides fiscal year 2026 net product revenues guidance of $2.325 billion to $2.425 billion, further indicating projected growth and stability [https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-preliminary-fiscal-year-2025-financial].

Exelixis actively participates in a variety of events, including investor conferences and its own dedicated R&D Day, to share updates and insights into its progress in oncology. The company's event calendar on exelixis.com serves as a central hub for upcoming engagements, often noting that more events are to be announced [https://ir.exelixis.com/event-calendar]. These events frequently feature webcast presentations, ensuring broad accessibility for interested parties.

In 2026, Exelixis management is scheduled to participate in several key investor conferences. These include the Goldman Sachs 47th Annual Global Healthcare Conference, the 2026 Jefferies Global Healthcare Conference, the Bernstein 42nd Annual Strategic Decisions Conference, and the BofA Securities Health Care Conference 2026 [https://ir.exelixis.com/event-calendar]. They will also participate in the 2026 RBC Capital Markets Global Healthcare Conference on May 19, 2026, and the 2026 Citizens Life Sciences Conference on March 11, 2026, with webcasts available for both [https://ir.exelixis.com/events/event-details/2026-rbc-capital-markets-global-healthcare-conference][https://ir.exelixis.com/events/event-details/2026-citizens-life-sciences-conference]. Additionally, in March 2026, Exelixis is slated to conduct fireside chats at upcoming investor conferences, including the TD Cowen 46th Annual Health Care Conference, with presentations webcast on its website [https://ir.exelixis.com/news-releases/news-release-details/exelixis-webcast-fireside-chats-part-upcoming-investor-2].

Exelixis also holds its own significant events, such as the Exelixis 2025 R&D Day, themed "Building Next-generation Oncology Franchises." This virtual event, scheduled for December 10, 2025, provides a comprehensive review of the company's research and development progress and outlines its strategic vision for future oncology efforts [https://ir.exelixis.com/events/event-details/exelixis-2025-rd-day-building-next-generation-oncology-franchises][https://ir.exelixis.com/news-releases/news-release-details/exelixis-webcast-virtual-2025-research-development-rd-day]. These events, along with financial results conference calls, highlight Exelixis' commitment to transparency and communication with the investment community and the broader scientific world.